Hereditary Transthyretin Amyloidosis Market Professional Industry Research Report 2030

Posted on
by

Hereditary Transthyretin Amyloidosis Market Professional Industry Research Report 2030

DelveInsight has added a new research study on Hereditary Transthyretin Amyloidosis Market Report with detailed information on the overview, market insights, drugs industry, treatment, growth, size, share, trends, during the forecast period of 2017 to 2030

 

Hereditary Transthyretin Amyloidosis Overview

Transthyretin Amyloidosis (ATTR) is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. ATTR is sub-classified as wild-type (wt) or hereditary; the latter is then further subdivided into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC).

 

Download Sample Copy @ https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market

 

Hereditary Transthyretin Amyloidosis Market: Regions Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

List of Companies involved in Hereditary Transthyretin Amyloidosis Market Report–

  • Vyndaqel/ Vyndamax: Pfizer
  • Onpattro: Alnylam Pharmaceuticals
  • Tegsedi: Akcea Therapeutics/ Ionis Pharmaceuticals
  • Vutrisiran: Alnylam Pharmaceuticals
  • AKCEA-TTR-LRx: Ionis Pharmaceuticals
  • AG 10: Eidos Therapeutics
  • CRX-1008: Corino Therapeutics Inc
  • PRX004: Prothena
  • And many others

 

Hereditary Transthyretin Amyloidosis Symptoms

hATTR amyloidosis involves many systems in the body and can result in a wide variety of symptoms, including sensory and motor, autonomic (e.g., diarrhea, hypotension, erectile dysfunction), and cardiac symptoms.

 

Hereditary Transthyretin Amyloidosis Market Disease

The disease continuum of hATTR amyloidosis encompasses patients who present with predominantly polyneuropathy symptoms (involving the nerves), known as familial amyloidotic polyneuropathy (FAP), and also patients who present with predominant cardiomyopathy symptoms (involving the heart), historically known as familial amyloidotic cardiomyopathy (FAC); however, many patients also experience gastrointestinal symptoms.

 

Hereditary Transthyretin Amyloidosis Diagnosis

Individuals affected by hATTR need an early and accurate diagnosis due to the potential progression of the disease. Misdiagnosis of hATTR is widespread because of its symptom’s commonality with that of numerous other diseases, giving rise to potentially ineffective or harmful treatment. Procedures commonly used to confirm the diagnosis of hATTR include blood tests, organ biopsies, and tissue biopsies.

 

Hereditary Transthyretin Amyloidosis Treatment

Current treatment options for patients with hATTR include some recently approved therapies, symptomatic treatment, and liver transplantation. Since TTR protein is mainly produced in the liver, transplanting a new liver should almost eliminate the production of variant protein and further halt the disease progression outside the brain and eyes.

 

Hereditary Transthyretin Amyloidosis Drugs

Recently few drugs are approved for the treatment of hATTR. The approved therapies include inotersen (Tegsedi), patisiran (Onpattro), tafamidis meglumine (Vyndaqel), and tafamidis (Vyndamax).

 

Hereditary Transthyretin Amyloidosis Market Insights

Patients with FAP usually die after 10–20 years post the onset of symptoms, and its symptoms are similar to numerous other diseases often leading to misdiagnosis; therefore, there is an immense need for early diagnosis, identification, and treatment of FAP for improving the patients’ quality of life

 

Hereditary Transthyretin Amyloidosis Market Outlook

The Hereditary Transthyretin Amyloidosis (hATTR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Transthyretin Amyloidosis (hATTR) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

 

Hereditary Transthyretin Amyloidosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis (hATTR) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Hereditary Transthyretin Amyloidosis (hATTR) market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

Hereditary Transthyretin Amyloidosis Market Report Scope

  • The report covers the descriptive overview of Hereditary Transthyretin Amyloidosis (hATTR), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Hereditary Transthyretin Amyloidosis (hATTR) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hereditary Transthyretin Amyloidosis (hATTR) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hereditary Transthyretin Amyloidosis (hATTR) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hereditary Transthyretin Amyloidosis (hATTR) market

 

Read Detailed Table of Content of Hereditary Transthyretin Amyloidosis Market Report

1 Key Insight

2 Executive Summary of hATTR

3 Hereditary Transthyretin Amyloidosis Market Overview at a Glance

3.1 Market Share (%) Distribution of Hereditary Transthyretin Amyloidosis in 2017

3.2 Market Share (%) Distribution of Hereditary Transthyretin Amyloidosis in 2030

4 Hereditary Transthyretin Amyloidosis (hATTR): Disease Background and Overview

5 Epidemiology and Patient Population

6 Current Treatment and Medical Practices

7 Unmet Needs

8 Marketed Drugs

9 Emerging Therapies

10 Phase III and Filed Drugs

11 Phase II Drugs

12 Phase I Drugs

13 Hereditary Transthyretin Amyloidosis: Market Analysis

14 Hereditary Transthyretin Amyloidosis (hATTR) Market Outlook

15 Market Drivers

16 Market Barriers

17 Reimbursement Scenario

18 Patient Support Programs

19 SWOT Analysis

20 KOL’s Views

21 Appendix

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

 

Hereditary Transthyretin Amyloidosis Market Report Highlights

  • In the coming years, Hereditary Transthyretin Amyloidosis (hATTR) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hereditary Transthyretin Amyloidosis (hATTR) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Hereditary Transthyretin Amyloidosis (hATTR). Launch of emerging therapies, will significantly impact the Hereditary Transthyretin Amyloidosis (hATTR) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hereditary Transthyretin Amyloidosis (hATTR)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

How Does This Hereditary Transthyretin Amyloidosis Market Insights Help?

  • The report will help in developing business strategies by understanding trends shaping and driving the Hereditary Transthyretin Amyloidosis (hATTR) market
  • To understand the future market competition in the Hereditary Transthyretin Amyloidosis (hATTR) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Hereditary Transthyretin Amyloidosis (hATTR) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Hereditary Transthyretin Amyloidosis (hATTR) market
  • To understand the future market competition in the Hereditary Transthyretin Amyloidosis (hATTR) market

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/